Korean J Nephrol.
2003 Jan;22(1):135-141.
3 Cases of Thrombotic Microangiopathy Induced by Low Dose Mitomycin-C
- Affiliations
-
- 1Department of Internal Medicine, College of Medicine, Kosin University, Busan, Korea. kongpot@ns.kosinmed.or.kr
- 2Department of Pathology, College of Medicine, Kosin University, Busan, Korea.
- 3Doctor Hwang's Clinic, Busan, Korea.
Abstract
- Mitomycin (MMC) is a naturally ocurring alkylating agent, introduced for clinical use as early as 1958. This drug is useful in the therapy of gastrointestinal carcinomas when used in combination with 5-fluorouracil. Nephrotoxicity among toxicities from MMC is unusual with cumulative doses less than 30 mg/m2. In large studies in which the incidence of MMC nephrotoxicity were assessed, 3-15% of patients developed total dose related renal dysfunction. Three patients in our clinical practice have developed thrombotic microangiopathy clearly related to MMC. We report the clinical and pathologic features of our cases. In view of the probable dose-related and delayed toxicity of MMC, it seems necessary to monitor regularly after initiation of chemotherapy. Early detection of the renal impairment and withdrawal of MMC might halt further progression of renal failure.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Antiphospholipid Syndrome Presenting as Recurrent Pancreatitis and Renal Thrombotic Microangiopathy
- Changes in VWF-cleaving Metalloprotease (ADAMTS 13) activity in the thrombotic microangiopathy after kidney tranplantation
- Slow, but complete, resolution of mitomycin-induced refractory thrombotic thrombocytopenic purpura after rituximab treatment
- Characteristics and management of thrombotic microangiopathy in kidney transplantation
- A Case of Locally Advanced Breast Cancer Complicated by Pulmonary Tumor Thrombotic Microangiopathy
